NCT05443932

Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

Dapagliflozin and Hydrochlorothiazide Treatment in Recurring Kidney Stone Patients - a Randomised Single Center Cross-over Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Medical University of Vienna · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Current prevention strategies in patients with recurrence of kidney stones show especially in high-risk patients a diversely and in the long-term not successful outcome in a sustainable number of cases. Recent studies have revealed that Dapagliflozin has the potential to decrease risk and incidence of urolithiasis events especially in patients suffering from Diabetes. The investigators propose that Dapagliflozin has the potential to increase the metabolic situation of hyperoxaluric patients with recurrence of urolithiasis. The investigators therefore test whether Dapagliflozin can decrease the oxalate excretion compared to the current strategy with Hydrochlorothiazide. The study may open up a new way of preventing urolithiasis in patients with high-risk of recurring urolithiasis.

Conditions

• Urolithiasis
• Hyperoxaluria

Interventions

Type	Name	Description
DRUG	Dapagliflozin	10mg Dapagliflozin daily for 8 weeks
DRUG	Hydrochlorothiazide	50mg Hydrochlorothiazide daily for 8 weeks

Timeline

• Start date: 2024-03-04
• Primary completion: 2024-12-31
• Completion: 2025-12-31
• First posted: 2022-07-05
• Last updated: 2023-10-23

Locations

1 site across 1 country: Austria